LOS ANGELES, Sept. 4 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) has committed to deploy Fidelity 100 Heart Monitors in more than 12 urban centers to screen for testing of sudden cardiac death and cardiovascular disease, events that will be financed by Athletes for Life, A Non Profit Foundation ("AFL"), through mobile centers though which AFL will bring health care to each community. AFL includes as its founders and members some of the world's greatest living and legendary athletes including, for example, current NFL star Reggie Bush, John Elway, Jim Brown, Marshall Falk, Olympic Gold Medal Winner Maurice Green, Jackie Joyner-Kersee, Gayle Sayers, Lee Elder, Anthony Munoz and Olympic Gold Medal Winner Willie Gault.
The events will be centered around screening and testing patients of all ages in everyday ambulatory environments, when the heart is at work. No other device can measure the full disease spectrum with the accuracy of the fidelity 100 when the subject is moving or when noise (artifact) is present. In the words of Signalife President and Chief Executive, Lowell T. Harmison, "It is impossible to level the playing field without giving everybody an opportunity to identify the signals about their health at the earliest possible opportunity. We are very thankful for AFL's insistence on assuring that the medical community eradicate the current cardiovascular crisis in America where $400 billion is spent annually with paltry preventative results for our middle and lower classes and the majority of society."
Under the arrangement, physicians will be present when AFL conducts its screening programs in various communities. AFL anticipates that it will conduct many of these programs using its prototypical moving "medical center truck". AFL has indicated that additional health care testing and screening will be provided in these centers. This screening program is a continuation of AFL's wellness program initially tested and developed at health clubs.
"The Company will provide a video on its website of the events, which will be covered by the print, internet and television media so that the entire world can see with its own eyes the importance of accurate signal detection," added AFL Founder, World-Class sprinter, Gold Medal Winner, and Super Bowl winner, Willie Gault.
AFL plans to have several additional members join as founders in preparation for these events, and Signalife will announce these superstars as they are signed. In California, track and screening locations have already been identified in Orange, Los Angeles, San Bernardino and San Francisco Counties and the public will be invited to meet the celebrity athletes -- and other celebrities -- within two weeks of each event.
AFL exclusively uses Signalife's Fidelity 100 for coronary testing, because the Signalife device is the only one able to detect the presence of coronary artery disease in an ambulatory environment, and for other reasons. Signalife is providing dozens of devices for the first series of events, at reduced price points for the AFL 501 (c)(3) charity.
For more information, please contact Signalife's corporate offices; however, the company will issue additional press releases as each event approaches.
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements:
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
|SOURCE Signalife, Inc.|
Copyright©2007 PR Newswire.
All rights reserved